HIGH.DE

SellHot Air

Cantourage Group SE · Healthcare · Germany · $68M cap · $38K/day traded

EUR 4.98 -2.0% · close 12 Oct · scored 14 Oct

Hot Air: Rising on momentum alone: weak business, rich price.

35
StockRank
Get score and insider alerts
Quality
42
Value
24
Momentum
59

As of 14 Oct 2026, MoatMap's StockRank for Cantourage Group SE (HIGH.DE) is 35/100, ranked against 24,000+ stocks in 35 markets (Quality 42, Value 24, Momentum 59, each scored against its sector).

Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →

P/E (TTM)
—
peers 21.1x
ROE
0.3%
peers 6.9%
D/E
0.0x
peers 0.3x
Dividend %
—
trailing yield
Loading 1Y...
PRICE (1Y) · EUR-15.6%
5.05.25.45.75.91 Sep22 Sep12 Oct
SMA 50SMA 200

Price checkNo clear trendExperimental

No clear trend: not near its 52-week low, and not in a steady uptrend.

SwingsBumpy

Swung more than 66% of stocks we rank over the past year (52% a year).

How this is worked out

StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.

The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.

In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.

What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.

What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.

Calm is not safe: a calm stock can still slide steadily.

Rules fixed before any data was fetched. Describes the chart, not a recommendation.

Close
EUR 4.98
RSI (14)
26.7
52-Week Range-27.4% from high
Low EUR 2.32High EUR 6.86

SCORE BREAKDOWN

Quality
42
ROIC
-10.6%33.7
ROE
0.3%44.4
GP/Assets
8.8%23.2
Op. Margin
4.6%51.7
FCF/Assets
—N/A
Piotroski
138.4
Int. Cover
-50.0x5.8
D/E Ratio
0.00x96.2
Current Ratio
39.70x98.9
Value
24
P/E (TTM)
—N/A
EV/EBITDA
—N/A
P/FCF
—N/A
P/B
—N/A
P/S
15.6x18.3
Div Yield
—N/A
Momentum
59
52W High %
73%57.1
RS 6M
-9%57.5
SMA 50/200
1.07x70.3
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+166%84.2
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$68M
P/E (Forward)
15.7x
Gross Margin
31.5%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of HIGH.DE are excluded.

TickerCompanyMkt CapStockRankSignal
HIGH.DECantourage Group SE(you)$68M35Sell
EVOEvotec SE$547M18Strong Sell
QUCYQuantum Cyber N.V.$111M21Sell
DMP.DEDermapharm Holding SE$2.2B90Strong Buy
IFRXInflaRx N.V.$289M34Sell
FYB.DEFormycon AG$380M38Hold
NNNNAnbio Biotechnology$266M19Strong Sell
1846.HKEuroEyes International Eye Clinic Limited$97M76Buy
VRXAVeraxa Biotech AG$197M0Strong Sell
ILM1.DEMedios AG$290M73Buy

Peer medians: ROE 6.9% · P/E 21.1x · Gross margin 45.7%

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

Cantourage Group SE (HIGH.DE): Stock Score Summary

Cantourage Group SE (HIGH.DE) has a MoatMap StockRank of 35/100 based on Quality (42/100), Value (24/100), and Momentum (59/100) factor scores. The current signal is SELL.

Key Financial Metrics

PriceEUR 4.98
Market Cap$68M
P/E (Forward)15.71
Return on Equity0.3%
Return on Invested Capital-10.6%
Debt/Equity0.00x
Gross Margin31.5%
Operating Margin4.6%
Revenue Growth172.6%

Cantourage Group SE operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (Germany).

Frequently Asked Questions

What is Cantourage Group SE’s (HIGH.DE) StockRank?
MoatMap’s StockRank for Cantourage Group SE (HIGH.DE) is 35/100, with a Sell signal. It is a composite of Quality (42), Value (24), and Momentum (59), each scored against its sector. The composite is then ranked across MoatMap’s universe of 24,000+ stocks.
Does Cantourage Group SE have an economic moat?
Cantourage Group SE (HIGH.DE) has a Quality factor score of 42/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Cantourage Group SE a buy, hold, or sell?
MoatMap’s current signal for Cantourage Group SE (HIGH.DE) is Sell, based on a StockRank of 35/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Cantourage Group SE in?
Cantourage Group SE (HIGH.DE) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (Germany).